Chen Bihua: insider trades.
Chen Bihua reported 7 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 1 open-market purchase ($5.0M) and 0 sales, across 2 companies.
- Transactions
- 7
- Purchases (P)
- 1
- Sales (S)
- 0
- Companies
- 2
- Name as filed
- Chen Bihua
Companies
| Company | Relationship | Transactions |
|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | Director, TenPercentOwner | 4 |
| BlossomHill Therapeutics, Inc. (BLSM) | TenPercentOwner, Director | 3 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-10 | BlossomHill Therapeutics, Inc. | P | 312,500 | $16 | 3,614,034 | Form 4 |
| 2026-08-10 | BlossomHill Therapeutics, Inc. | C | 1,599,993 | — | 1,599,993 | Form 4 |
| 2026-08-10 | BlossomHill Therapeutics, Inc. | C | 1,701,541 | — | 3,301,534 | Form 4 |
| 2026-07-01 | BridgeBio Oncology Therapeutics, Inc. | J | 130,865 | $0 | 6,083,221 | Form 4 |
| 2026-07-01 | BridgeBio Oncology Therapeutics, Inc. | J | 1,704,862 | $0 | 5,010,332 | Form 4 |
| 2026-07-01 | BridgeBio Oncology Therapeutics, Inc. | J | 2,692,459 | $0 | 4,879,995 | Form 4 |
| 2026-07-01 | BridgeBio Oncology Therapeutics, Inc. | J | 4,528,186 | $0 | 0 | Form 4 |
Questions
What stock did Chen Bihua buy or sell?
Chen Bihua reported 7 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 1 open-market purchase ($5.0M) and 0 sales, across 2 companies.
Is Chen Bihua the same person as other filers with this name?
This page covers SEC CIK 1599214 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/chen-bihua-1599214.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.